



Zilretta™ (triamcinolone acetonide extended-release injectable suspension)

When requesting Zilretta (triamcinolone acetonide extended-release injectable suspension), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Coverage Guidelines

Osteoarthritis pain of the knee

The individual must meet **all** of the following criteria for approval:

- Has a diagnosis of osteoarthritis of knee;
- Has not previously received Zilretta injection;
- Has had an inadequate response, intolerance, or contraindication to at least 2 of the following therapies: acetaminophen [e.g., Tylenol®], non-steroidal anti-inflammatory drug(s) [e.g., Advil®, Motrin®], or tramadol (Ultram®); AND
- Has had an inadequate response to previous intra-articular corticosteroid injection.

Approval duration: 1 dose

Recommended Dosing

Approve up to a maximum of 32mg, administered as an intra-articular injection, once.

References

1. Zilretta prescribing information. Burlington, MA. Flexion Therapeutics, Inc., May 2018. Available at: http://www.zilrettalabel.com/PI.pdf?_ga=2.208921874.144372298.1510243580-582686676.1510243580. Accessed September 24, 2020.
2. Kolasinski, SL, Tuhina N, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arth Care Res.* 2020;72(2):149-162.
3. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann Rheum Dis.* 2003;62(12):1145-1155.
4. Bruyere, O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Seminars in Arthritis and Rheumatism.* 2014;44:253-264.